Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa. by Villa, Giovanni et al.
EClinicalMedicine 18 (2020) 100231
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: https://www.journals.elsevier.com/eclinicalmedicineResearch PaperDetermining virological suppression and resuppression by point-of-care
viral load testing in a HIV care setting in sub-Saharan Africa
Giovanni Villaa,b, Adam Abdullahia, Dorcas Owusuc, Colette Smithd, Marilyn Azumahe,
Laila Sayeedf, Harrison Austina, Dominic Awuahe, Apostolos Beloukasa,g, David Chadwickf,
Richard Phillipsc,e, Anna Maria Gerettia,*
a Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom
b Department of Global Health & Infection, Brighton & Sussex Medical School, University of Sussex, Brighton, United Kingdom
c Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
d Institute of Global Health, University College London, London, United Kingdom
eDepartment of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana
f Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom
g Department of Biomedical Sciences, University of West Attica, Athens, GreeceA R T I C L E I N F O
Article History:
Received 22 October 2019
Revised 27 November 2019
Accepted 2 December 2019
Available online xxx* Corresponding author at: Institute of Infection & Glo
pool, 8 West Derby Street, Liverpool L69 7BE, United Kin
E-mail address: a.m.geretti@liverpool.ac.uk (A.M. Ger
https://doi.org/10.1016/j.eclinm.2019.12.001
2589-5370/© 2019 Published by Elsevier Ltd. This is an oA B S T R A C T
Background: This prospective pilot study explored same-day point-of-care viral load testing in a setting in
Ghana that has yet to implement virological monitoring of antiretroviral therapy (ART).
Methods: Consecutive patients accessing outpatient care while on ART underwent HIV-1 RNA quantiﬁcation
by Xpert. Those with viraemia at the ﬁrst measurement (T0) received immediate adherence counselling and
were reassessed 8 weeks later (T1). Predictors of virological status were determined by logistic regression
analysis. Drug resistance-associated mutations (RAMs) were detected by Sanger sequencing.
Findings: At T0, participants had received treatment for a median of 8¢9 years; 297/333 (89¢2%) were on
NNRTI-based ART. The viral load was 40 copies/mL in 164/333 (49¢2%) patients and 1000 copies/mL in 71/
333 (21¢3%). In the latter group, 50/65 (76¢9%) and 55/65 (84¢6%) harboured NRTI and NNRTI RAMs, respec-
tively, and 27/65 (41¢5%) had 1 tenofovir RAM. Among 150/164 (91¢5%) viraemic patients that reattended
at T1, 32/150 (21¢3%) showed resuppression <40 copies/mL, comprising 1/65 (1¢5%) subjects with T0 viral
load 1000 copies/mL and 31/85 (36¢5%) subjects with lower levels. A T0 viral load 1000 copies/mL and
detection of RAMs predicted ongoing T1 viraemia independently of self-reported adherence levels. Among
participants with T0 viral load 1000 copies/mL, 23/65 (35¢4%) showed resuppression <1000 copies/mL; the
response was more likely among those with higher adherence levels and no RAMs.
Interpretation: Same-day point-of-care viral load testing was feasible and revealed poor virological control
and suboptimal resuppression rates despite adherence counselling. Controlled studies should determine
optimal triaging modalities for same-day versus deferred viral load testing.
Funding: University of Liverpool, South Tees Infectious Diseases Research Fund
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Plasma HIV-1 RNA levels provide a direct measure of the efﬁcacy
of antiretroviral therapy (ART), predicting immunological and clinical
outcomes and the risk of transmission [1]. Modelling indicates that
differentiating care based on the viral load is cost-effective forlow-income settings [2], whereby suppressed patients attend clinic
visits less frequently and more resources are focused on patients
with viraemia. The approach is endorsed by the WHO, whose guide-
lines indicate viraemic patients should receive adherence counsel-
ling, followed by a repeat viral load measurement taken 36 months
later [3]. There is evidence indicating that resuppression is common
after interventions to re-enforce adherence, especially in patients
with a low viral load [4,5]. A change of the treatment regimen is only
recommended once a viral load 1000 copies/mL is conﬁrmed [3].
Access to ART has been expanding in sub-Saharan Africa. Of the
estimated 25¢7 million HIV-positive individuals, 15¢4 million (60%)
were receiving treatment in 2018, aiming for 95% by 2030 [6].
Research in context
Evidence before this study
We searched PubMed for studies that used the Cepheid
Xpert HIV-1 viral load assay for monitoring HIV-positive
patients receiving antiretroviral therapy (ART) in sub-Saharan
Africa. The search terms were “Cepheid”, “Xpert”, “HIV”, “viral
load” and “Africa”. We found ﬁve published studies that investi-
gated the technical performance of the assay when compared
to centralised testing by standard laboratory-based assays. One
study used the Xpert assay for on-site testing of patients
deemed to be at increased risk of virological failure; in this
study, viral load testing and subsequent adherence counselling
were deferred by 13 weeks. No previous published study
used the Xpert assay to provide same-day viral load testing fol-
lowed by immediate, viral load-informed adherence counsel-
ling, and no previous published study used the Xpert assay to
assess rates of resuppression after adherence counselling. Pre-
vious published studies often suffered from high rates of loss to
follow-up, which limits the interpretation of the ﬁndings.
Added value of this study
The study demonstrates the feasibility of viral load testing at
point of care in a HIV programmatic setting in sub-Saharan
Africa where ART is available free of charge but there is no rou-
tine provision of viral load testing. Results were delivered to
patients on the same day and proved helpful in guiding imme-
diate adherence counselling. The results provide novel data for
Ghana and raise concern. In a HIV cohort established on long-
term, predominantly NNRTI-based ART without access to viro-
logical monitoring, nearly half had a detectable viral load at the
ﬁrst test and 1 in 5 had a viral load 1000 copies/mL. One
important aspect was the high retention of viraemic patients
into follow-up, with 91¢5% reattending after 8 weeks. Despite
improvements in self-reported adherence, none of the patients
with viral load 1000 copies/mL achieved resuppression
<40 copies/mL while continuing NNRTI-based ART (and only a
subset resuppressed <1000 copies/mL), and the virological out-
comes were related to the presence of drug resistance.
Implications of all the available evidence
In an epidemiological context where patients have been
receiving long-term NNRTI-based ART in the absence of viro-
logical monitoring, detection of a viral load 1000 copies/mL
can serve as a trigger for an immediate change of therapy both
to limit the risk of disease progression and prevent onward
transmission of highly drug-resistant strains. There is a need to
survey whether the complex resistance patterns observed in
patients with viral load 1000 copies/mL, including a high
prevalence of tenofovir RAMs, affect the efﬁcacy of novel HIV
treatment regimens. There is also a need to determine the
long-term outcomes of the subset of patients that resuppressed
<1000 copies/mL but remained viraemic while continuing
NNRTI-based ART. To prove effective for sub-Saharan Africa,
viral load testing at point of care requires operational reﬁne-
ments, including modalities for effective triaging of patients to
same-day versus deferred testing, which should be evaluated
in controlled studies.
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gradually expand; however, routine access faces signiﬁcant barriers
due to overburdened healthcare systems, ﬁnancial constraints, poor
training, and weak transport and laboratory infrastructure [7]. Imple-
mentation of viral load testing in sub-Saharan Africa may beneﬁt fromsolutions that reduce the number of clinic visits, which in turn is likely
to promote retention into care and improved clinical outcomes.
There is growing interest in novel platforms that enable viral load
testing outside specialised laboratories. The Cepheid Xpert HIV-1
viral load assay was the ﬁrst to receive WHO endorsement for use in
resource-limited settings [8], and has comparable performance to
laboratory-based assays [9]. Xpert is widely available across sub-
Saharan Africa for the diagnosis of tuberculosis. Its modular, car-
tridge-based self-contained system can be used by non-specialised
personnel and offers a low risk of contamination, a fast turn-around
time for results, and no requirement for sample batching, features
that make the platform suitable for same-day testing at point of care
[10]. In comparative studies in Botswana, Malawi, South Africa, and
Kenya, the Xpert HIV-1 viral load assay showed a high level of agree-
ment with standard laboratory-based real-time PCR assays [1115].
This prospective pilot study reports on same-day point-of-care
(POC) HIV-1 RNA quantiﬁcation by Xpert in a typical programmatic
HIV centre in Ghana where ART is provided free of charge but viro-
logical monitoring of treated patients is yet to become part of routine
care. POC viral load results were used to fast track viraemic patients
to immediate adherence counselling and POC viral load testing was
used to measure resuppression at the follow-up visit 8 weeks later.
Factors associated with virological suppression and resuppression
were identiﬁed, producing data that may help guide policy and
inform the design of larger controlled studies.
2. Methods
2.1. Setting and sample size
The setting was the HIV clinic of the Komfo Anokye Teaching Hos-
pital (KATH), a 1200-bed facility in the city of Kumasi and the sec-
ond-largest hospital in Ghana, serving a population of around
10 million people in the Ashanti Region. Approval was granted by the
Ethics Committee of the Kwame Nkrumah University of Science and
Technology in Kumasi. Eligible participants were HIV-positive adults
(18 years) attending for routine HIV care. Sample size was deter-
mined by estimating a total KATH HIV cohort of 4500 patients and a
rate of viraemia (>40 copies/mL) of 40% (5% precision) [16].
2.2. Patients’ ﬂow
In February 2018 (T0), consecutive patients attending 4 out-patient
clinics over 2 weeks were offered participation in the study and all
accepted (Fig. 1). At T0, participants underwent blood sampling and
completed a simple structured questionnaire, which was administered
by trained local interpreters to overcome literacy barriers. The question-
naires collected information on adherence (T0 adherence questionnaire
1, see below) and socio-economic and life-style parameters: having
enough food to be able to eat regular meals (always; most days; some of
the time; never), alcohol consumption (never; occasionally [not more
than once a week]; regularly [more than once a week]), and any use of
traditional or herbal remedies. After completing the questionnaires,
ART-naïve patients and subjects who had discontinued ART were
directed to initiating or reinitiating treatment. Participants taking ART
were invited to wait for the viral load result. Patients with virological
suppression<40 copies/mL were informed and returned to routine care.
Patients with viraemia were fast-tracked to immediate adherence
review with the local, trained clinic nurses; counselling was informed by
the viral load result and used a simple structured questionnaire (T0
adherence questionnaire 2, see below); potential reasons for poor adher-
ence were addressed by the clinic nurses using the standard local format
for adherence counselling, which includes eliciting any problemwith tol-
erability or issues of forgetfulness, personal belief about the beneﬁts of
treatment, available support and disclosure of HIV status, and suggested
strategies to improve adherence such as use of memory aids (e.g., setting
Fig. 1. Patients’ ﬂow.
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were invited to attend a follow-up visit 8 weeks later (May 2018; T1),
when POC viral load testing was repeated and adherence reassessed
with a simple structured questionnaire (T1 adherence questionnaire, see
below). CD4 cell counts and full blood counts were measured at KATH.
All patients with CD4 count <200 cells/mm3 underwent urgent clinical
review. Available clinical data were collected from themedical records.2.3. Adherence measures
The T0 questionnaire 1, which was administered at study entry prior
to receipt of the viral load result, asked participants about any previous
treatment interruption, deﬁned as discontinuation of all antiretroviral
drugs for  3 consecutive days since ﬁrst starting ART, and how the
patient would describe adherence in the previous 3 months on an ordi-
nal visual analogue scale (VAS) ranging from 0% (complete non-adher-
ence) to 100% (complete adherence) in 10% increments. The T0
questionnaire 2 was administered at adherence review to patients with
viraemia, after they had received their viral load result; it asked about
the number of doses missed in the previous month (none; 1; 2 to 3;
>3). The T1 questionnaire, which was administered at follow-up after
the patients had received their repeat viral load result, collected the VAS
and the number of missed doses in the previous month (none; 1; 2 to 3;
>3). The number of doses missed in the previous month according to
the T0 questionnaire 2 and the T1 questionnaire were used to calculate
an adherence score ranging from 3 points (no missed doses, best adher-
ence) to 0 points (>3missed doses, worst adherence).2.4. Viral load testing
Plasma was separated from whole blood in EDTA by centrifuga-
tion at 2000 g for 10 min and tested by the Xpert HIV-1 viral load
assay (Cepheid, Sunnyvale, USA). The assay quantiﬁes HIV-1 Group
M, N and O with a range of 40 to 107 copies/mL and provides results
within 90 min [17]. The Xpert was located in a room adjacent to the
clinical area. All patient received the result on the same day.2.5. Resistance testing
If the T0 viral load was 200 copies/m, plasma virus was retro-
spectively tested for the presence of resistance-associated mutations
(RAMs) in reverse transcriptase (RT, amino acids 1335) and prote-
ase (amino acids 199) using Sanger sequencing as previously
described [18]. Major RAMs and genotypic susceptibility scores (GSS)
were determined using the Stanford HIV Drug Resistance database
(v8¢8); each drug in the regimen scored 0 with high-level resistance,
0¢25 with intermediate resistance, 0¢5 with low level resistance and 1
with potential low-level resistance or full susceptibility. HIV-1 sub-
types were determined by phylogenetic analysis.2.6. Analyses
Fisher’s, chi-squared, or Mann-Whitney tests were used to compare
the characteristics of study participants according to the T0 viral load.
The correlation between number of treatment interruptions and T0 VAS
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correlation analysis. Factors associated with viral load suppression <40
and <1000 copies/mL at T0 and with resuppression <40 and
<1000 copies/mL at T1 were explored by multivariable logistic regres-
sion analysis. Variables with p < 0¢1 in the univariable models were
included in the multivariable models. The analysis of factors associated
with viral load suppression and resuppression did not include the T0
CD4 cell count, which was analysed separately for its association with
the T0 viral load using univariable linear regression analysis. The analy-
sis of factors associated with viral load resuppression did not include
detection of NNRTI RAMs as these were part of the GSS calculation. Col-
linearity was assessed by calculating the variance inﬂation factor.
Changes in adherence scores and viral load between T0 and T1 were
analysed by Wilcoxon signed rank test. Statistical analyses were per-
formed with STATA, version 14 (StataCorp Inc, College Station, USA).
3. Results
3.1. Study population at T0
The characteristics of the 333 patients who were on ART at T0 are
shown in Table 1. The cohort included a majority of women (246/
333, 73¢9%), was long established on ART (median 8¢9 years) andTable 1
Baseline characteristics of the study population according to the T0 viral load.
Characteristics Total
<40
Total number (%) 333 (100) 169
Female gender, n (%) 246 (73¢9) 135
Age, median years (IQR) 48 (4254) 49
Time since HIV diagnosis,
median years (IQR)
9¢5 (6¢312¢0) 10¢1
In stable partnership, n (%) 165 (49¢6) 73
Children in the household,
median number (IQR)
3 (24) 3
Education level, n (%) none/primary 171 (51¢4) 95
secondary/post-secondary 162 (48¢7) 74
Enough food, n (%) always/most days 267 (80¢2) 131
some of the time/never 61 (18¢3) 37
no data 5 (1¢5) 1
Alcohol consumption, n (%) never 317 (95¢2) 164
occasionally 13 (3¢9) 5
regularly 3 (0¢9) 0
Traditional or herbal
remedies, n (%)
11 (3¢3) 4
Duration of ART,
median years (IQR)
8¢9 (5¢711¢3) 9¢5
Third agent, n (%) NNRTIa 297 (89¢2) 155
PI/rb 36
NRTI backbone, n (%) TDF/3TC 187 (56¢2) 92
AZT/3TC 141 (42¢3) 76
Treatment interruptions since
ﬁrst starting ART, n (%)
none 250 (75¢1) 147
1 42 (12¢6) 8
23 36 (10¢8) 12
> 3 5 (1¢5) 2
VAS score, median% (IQR) 100 (100100) 100 (100100) 100
VAS score category, n (%) 100% 258 (77¢5) 146
90100% 37 (11¢1) 13
8090% 23 (6¢9) 7
<80% 15 (4¢5) 3
CD4 count, median cells/mm3 (IQR) 626 (373840) 757
CD4 count <200 cells/mm3, n (%) 34 (10¢2) 6
HIV-1 RNA, median log10 copies/mL 1¢3 (0¢702¢6) 1¢3
Abbreviations: ABC=abacavir; ART=antiretroviral therapy; ATV/r=ritonavir-boosted ataz
boosted lopinavir; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleos(t)
inhibitor; 3TC=lamivudine; TDF=tenofovir disoproxil fumarate; VAS=visual analogue scale.
a NNRTI-based regimens: TDF/3TC EFV n = 155 (46¢6%), TDF/3TC NVP n = 12 (3¢6%), AZT/3
b PI/r-based regimens: TDF/3TC LPV/r n = 18 (5¢4%), TDF/3TC ATV/r n = 2 (0¢6%), AZT/3TC LPVshowed a median CD4 count of 626 cells/mm3. Most participants
(297/333, 89¢2%) were receiving an NNRTI (predominantly efavirenz)
whereas 36/333 (10¢8%) were on a ritonavir-boosted protease inhibi-
tor (PI/r, predominantly lopinavir/ritonavir), each usually combined
with the NRTIs tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)
(187/333, 56¢2%) or zidovudine (AZT)/3TC (141/333, 42¢3%). Overall,
164/333 (49¢2%) patients showed a viral load 40 copies/mL, with
median levels in this group of 2¢6 log10 copies/mL (IQR 2¢04¢4); 71/
333 (21¢3%) had a viral load 1000 copies/mL. The CD4 count was
134 cells/mm3 lower for each 1 log10 copies/mL increase in viral load
(95% CI 155 to 113; p < 0¢0001).
3.2. Factors associated with the T0 viral load
The analysis of factors associated with the T0 viral load is shown in
Table 2. The number of treatment interruptions and VAS score were sig-
niﬁcantly correlated (Spearman’s rho 0¢45; p < 0.0001) and were
therefore modelled separately. After adjustment, viral load suppression
<40 copies/mL was more likely in females, patients with sufﬁcient food
at least some of the time, those that either did not report treatment
interruptions or had a higher VAS score, and (marginally) among older
patients. Viral load suppression <1000 copies/mL was more likely
among older patients, those receiving TDF/3TC rather than AZT/3TC,T0 viral load (copies/mL) p
40199 200999 1000
(100) 63 (100) 30 (100) 71 (100) 
(79¢9) 41 (65¢1) 20 (66¢7) 50 (70¢4) 0¢07
(4255) 48 (4254) 46 (4252) 47 (4150) 0¢11
(6¢612¢4) 9¢3 (6¢711¢7) 7¢1 (2¢310¢9) 9¢2 (6¢411¢8) 0¢20
(43¢2) 37 (58¢7) 12 (40¢0) 43 (60¢6) 0¢02
(14) 3 (14) 3 (14) 3 (24) 0¢86
(56¢2) 24 (38¢1) 11 (36¢7) 41 (57¢8) 0¢02
(43¢8) 39 (61¢9) 19 (63¢3) 30 (42¢3)
(77¢5) 51 (81¢0) 26 (86¢7) 59 (83¢1) 0¢48
(21¢9) 9 (14¢3) 4 (13¢3) 11 (15¢5)
(0¢6) 3 (4¢8) 0 (0) 1 (1¢4)
(97¢0) 61 (96¢8) 28 (93¢3) 64 (90¢1) 0¢07
(3¢0) 1 (1¢6) 1 (3¢3) 6 (8¢5)
(0) 1 (1¢6) 1 (3¢3) 1 (1¢4)
(2¢4) 0 (0) 1 (3¢3) 6 (8¢5) 0¢04
(5¢911¢3) 8¢3 (4¢511¢3) 8¢0 (2¢110¢8) 8¢9 (6¢311¢2) 0¢47
(91¢7) 55 (87¢3) 21 (70¢0) 66 (93¢0) 0¢01
(10¢8) 14 (8¢3) 8 (12¢7) 9 (30¢0) 5 (7¢0)
(54¢4) 43 (68¢3) 18 (60¢0) 34 (47¢9) 0¢05
(45¢0) 18 (28¢6) 10 (33¢3) 37 (52¢1)
(87¢0) 41 (65¢1) 21 (70¢0) 41 (57¢8) <0¢001
(4¢7) 11 (17¢5) 5 (16¢7) 18 (25¢4)
(7¢1) 10 (15¢9) 4 (13¢3) 10 (14¢1)
(1¢2) 1 (1¢6) 0 (0) 2 (2¢8)
(90100) 100 (90100) 100 (85100) 0¢001
(86¢4) 45 (71¢4) 20 (66¢7) 47 (66¢2) <0¢001
(7¢7) 9 (14¢3) 9 (30¢0) 6 (8¢5)
(4¢1) 6 (9¢5) 1 (3¢3) 9 (12¢7)
(1¢8) 3 (4¢8) 0 (0) 9 (12¢7)
(575970) 640 (445774) 611 (390799) 234 (155410) <0¢001
(3¢6) 1 (1¢6) 1 (3¢3) 26 (36¢6) <0¢001
(0¢701¢3) 1¢9 (1¢82¢1) 2¢5 (2¢42¢7) 4¢6 (4¢05¢3) 
anavir; AZT=zidovudine; EFV=efavirenz; IQR=interquartile-range; LPV/r=ritonavir-
ide reverse transcriptase inhibitor; NVP=nevirapine; PI/r=ritonavir-boosted protease
TC EFV n = 60 (18¢0%), AZT/3TC NVP n = 70 (21¢0%).
/r n = 10 (3¢0%), AZT/3TC ATV/r n = 1 (0¢3%), ABC 3TC ATV/r n = 1 (0¢3%), Other n = 4 (1¢2%).
Table 2
Univariable and multivariable logistic regression analysis of factors associated with a T0 viral load <40 copies/mL.
Variable Univariable analysis Multivariable analysisa
Model 1 Model 2
OR 95% CI p OR 95% CI p OR 95% CI p
Gender female vs male 1¢90 1¢153¢12 0¢01 1¢92 1¢093¢36 0¢02 1¢91 1¢103¢32 0¢02
Age per 5 years older 1¢13 0¢991¢29 0¢06 1¢13 0¢981¢30 0¢09 1¢15 1¢001¢32 0¢06
Enough food never vs at least some of the time 0¢30 0¢090¢95 0¢04 0¢25 0¢070¢95 0¢04 0¢22 0¢060¢79 0¢02
Alcoholb yes vs no 0¢19 0¢021¢64 0¢13
Traditional or herbal remedies yes vs no 0¢54 0¢161¢89 0¢34
Third agent PI/r vs NNRTI 0¢58 0¢291¢18 0¢14
NRTI backbone AZT/3TC vs TDF/3TC 0¢83 0¢531¢28 0¢40
Duration of ART per 1 year longer 1¢03 0¢981¢09 0¢29
Treatment interruptions 1 vs none 0¢25 0¢150¢44 <0¢001 0¢29 0¢160¢52 <0¢001 
VAS score per 10% score higher 1¢69 1¢262¢26 <0¢001  1¢52 1¢132¢06 0¢01
Time since HIV diagnosis per year longer 1¢05 0¢991¢11 0¢12
T0 CD4 count per 100 cells/mm3 higher 1¢38 1¢271¢51 <0¢001  
Abbreviations: ART=antiretroviral therapy; AZT=zidovudine, CI=conﬁdence interval; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleos(t)ide reverse tran-
scriptase inhibitor; OR=odds ratio; PI/r=ritonavir-boosted protease inhibitor; 3TC=lamivudine; TDF=tenofovir disoproxil fumarate; VAS=visual analogue scale.
a Model 1 includes the reported history of treatment interruption whereas Model 2 includes the VAS score; neither model includes the CD4 cell count, which was analysed
separately.
b Occasional or regular use.
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higher VAS score (Table 3).
3.3. T1 viral load
Among T0 participants with a viral load 40 copies/mL, 150/164
(91¢5%) returned at T1. The distribution of T1 viral load according to the
T0 viral load and ART regimen is shown in Table 4. Between T0 and T1,
the median viral load (in log10 copies/mL) changed from 2¢6 (IQR
2¢04¢4) to 2¢3 (IQR 1¢73¢6) (p = 0¢0017) and 32/150 (21¢3%) patients
achieved resuppression <40 copies/mL. Among the 122/150 (81¢3%)
patients continuing NNRTI-based ART, the viral load changed from 2¢5
(IQR 1¢94¢2) to 2¢4 (IQR 1¢74¢1) (p = 0¢07); 25/122 (20¢5%) achieved
resuppression <40 copies/mL. Among the 21/150 (14¢0%) patients con-
tinuing PI/r-based ART, the viral load changed from 2¢6 (IQR 2¢13¢0) to
2¢2 (IQR 1¢32¢8) (p = 0¢042); 6/21 (28¢6%) achieved resuppression
<40 copies/mL. There were 7/150 (4¢7%) patients who changed from
NNRTI-based to PI/r-based ART after T0 owing to low CD4 cell counts; in
this subset, the viral load changed from 5¢3 (IQR 4¢95¢8) to 2¢2 (IQR
1¢62¢5) (p = 0¢018); 1/7 (14¢3%) achieved resuppression<40 copies/mL.
Among subjects with T0 viral load 40999 copies/mL, 31/85 (36¢5%)Table 3
Univariable and multivariable logistic regression analysis of predictors of a T0 viral load
Variable Univaria
OR 95% C
Gender female vs male 1¢25 0¢70
Age per 5 years older 1¢18 1¢01
Enough food never vs at least some of the time 0¢43 0¢15
Alcoholb yes vs no 0¢26 0¢05
Traditional or herbal remedies yes vs no 0¢21 0¢06
Third agent PI/r vs NNRTI 1¢77 0¢66
NRTI backbone AZT/3TC vs TDF/3TC 0¢62 0¢37
Duration of ART per 1 year longer 0¢99 0¢92
Treatment interruptions 1 vs none 0¢35 0¢20
VAS score per 10% higher 1¢60 1¢24
Time since HIV diagnosis per year longer 1¢00 0¢93
T0 CD4 count per 100 cells/mm3 higher 1¢95 1¢66
Abbreviations: ART=antiretroviral therapy; AZT=zidovudine, CI=conﬁdence interval; N
transcriptase inhibitor; OR=odds ratio; PI/r=ritonavir-boosted protease inhibitor; 3TC=la
a Model 1 includes the reported history of treatment interruption whereas Model 2 i
lysed separately.
b Occasional or regular use.achieved resuppression <40 copies/mL. Only 1 subject among the 65
(1¢5%) with T0 viral load 1000 copies/mL achieved resuppression <40
copies/mL; this subject was in the subset that changed to PI/r-based ART
after T0. Among participants with T0 viral load 1000 copies/mL, 23/65
(35¢4%) had a T1 viral load 40 but <1000 copies/mL, comprising 19/60
(31.7%) patients on NNRTI-based ART and 4/5 (80¢0%) on PI/r-based ART.
3.4. Factors associated with the T1 viral load
The analysis of factors associated with the T1 viral load are shown
in Table 5. The T0 viral load and GSS were signiﬁcantly correlated
(Spearman’s rho 0¢66; p<0¢0001) and were therefore modelled
separately. After adjustment, the likelihood of resuppression
<40 copies/mL decreased by nearly 3-fold for each 1 log10 copies/mL
increase in T0 viral load.When the T0 viral load was analysed as a cate-
gorical variable, resuppression <40 copies/mL was over 30-fold less
likely with a T0 viral load1000 copies/mL. In the model including the
GSS, the likelihood of resuppression <40 copies/mL almost halved
with each 0¢5 unit decrease in GSS; the presence of NNRTI RAMs
reduced by almost 15-fold the likelihood of resuppression
<40 copies/mL. A separate analysis considered the likelihood of viral<1000 copies/mL.
ble analysis Multivariable analysisa
Model 1 Model 2
I p OR 95% CI p OR 95% CI p
2¢23 0¢46
1¢39 0¢04 1¢20 1¢021¢43 0¢03 1¢21 1¢021¢43 0¢03
1¢23 0¢12
1¢33 0¢11
0¢71 0¢01 0¢34 0¢091¢32 0¢12 0¢35 0¢091¢35 0¢13
4¢74 0¢25
1¢05 0¢08 0¢44 0¢240¢79 0¢01 0¢42 0¢230¢77 0¢01
1¢05 0¢69
0¢61 <0¢001 0¢42 0¢230¢79 0¢01 
2¢07 <0¢001  1¢48 1¢121¢96 0¢01
1¢07 0¢98
2¢29 <0¢001  
NRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleos(t)ide reverse
mivudine; TDF=tenofovir disoproxil fumarate; VAS=visual analogue scale.
ncludes the VAS score; neither model includes the CD4 cell count, which was ana-
Table 4
The T1 viral load among patients with T0 viraemia, by T0 viral load and ART regimen.
T0 ART regimen T0 viral load (copies/mL) T1 viral load (copies/mL)
<40 40199 200999 1000
NNRTI-based, n (%) 40199 18 (36%) 24 (48%) 8 (16%) 0 (0%)
200999 7 (37%) 5 (26%) 6 (32%) 1 (5%)
1000 1 (2%)a 7 (12%)b 11 (18%)b 41 (68%)
PI-based, n (%) 40199 3 (38%) 4 (50%) 0 (0%) 1 (13%)
200999 3 (38%) 1 (13%) 2 (25%) 2 (25%)
1000 0 (0%) 2 (40%) 2 (40%) 1 (20%)
Total All strata 32 (21%) 43 (29%) 29 (19%) 46 (31%)
Abbreviations: ART=antiretroviral therapy; NNRTI=non-nucleoside reverse transcriptase inhibitor;
PI=protease inhibitor.
a The patient switched to a PI/r-based regimen between T0 and T1.
b Three patients switched to a PI/r-based regimen between T0 and T1.
Table 5
Univariable and multivariable logistic regression analysis of factors associated with lack of resuppression <40 copies/mL at T1.
Variable Univariable analysis Multivariable analysisa
Model 1 Model 2 Model 3
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Gender female vs male 0¢96 0¢412¢22 0¢92
Age per 5 years older 0¢98 0¢771¢25 0¢89
Enough food never vs at least some of the
time
0¢53 0¢151¢88 0¢33
Alcoholb yes vs no 1¢09 0¢1210¢1 0¢94
Traditional or herbal
remedies
yes vs no 1¢66 0¢1914¢3 0¢64
Third agent PI/r vs NNRTI 0¢63 0¢221¢79 0¢39
NRTI backbone AZT/3TC vs TDF/3TC 0¢55 0¢251¢23 0¢15
Duration of ART per 1 year longer 1¢01 0¢911¢12 0¢83
Treatment interruptions 1 vs never 0¢65 0¢301¢43 0¢28
T1 VAS per 10% higher 0¢67 0¢441¢00 0¢05 0¢76 0¢451¢29 0¢31 0¢75 0¢431¢29 0¢30 0¢73 0¢441¢20 0¢21
Change in adherence score per unit increase 1¢02 0¢761¢37 0¢89
Time since HIV diagnosis per year longer 0¢99 0¢891¢09 0¢81
T0 CD4 count per 100 cells/mm3 higher 0¢80 0¢690¢92 0¢001   
T0 viral load per 1 log10 copies/mL higher 3¢02 1¢715¢32 <0¢001 2¢81 1¢594¢98 <0¢001  
T0 viral load 1000 vs <1000 copies/mL 36¢7 4¢85278 <0¢001  31¢6 4¢15240 0¢001 
T0 GSS scorec per 0¢5 higher 0¢55 0¢390¢79 0¢001   0¢58 0¢41082 0¢002
T0 NNRTI RAMs yes vs no 14¢5 3¢3163¢5 <0¢001   
Abbreviations: ART=antiretroviral therapy; AZT=zidovudine; CI=conﬁdence interval; GSS=genotypic susceptibility score; NNRTI=non-nucleoside reverse transcriptase
inhibitor; NRTI=nucleos(t)ide reverse transcriptase inhibitor; OR=odds ratio; PI/r=ritonavir-boosted protease inhibitor; RAMs=resistance-associated mutations; 3TC=lami-
vudine; TDF=tenofovir disoproxil fumarate; VAS=visual analogue scale.
a Model 1 and Model 2 include the T0 viral load as a continuous and categorical variable respectively, and do not include the T0 GSS score; Model 3 includes the T0 GSS
and does not include the T0 viral load.
b Occasional or regular use.
c A GSS of 3 was arbitrarily assigned to patients with viral load <200 copies/mL and to 5 patients with viral load 200400 copies/mL that did not yield a sequencing
amplicon in 2 attempts (based on the absence of RAMs in other samples with viral load 200400 copies/mL).
6 G. Villa et al. / EClinicalMedicine 18 (2020) 100231load resuppression <1000 copies/mL among patients with T0 viral
load 1000 copies/mL (Table 6). The T1 VAS and the GSS indepen-
dently predicted viral load resuppression <1000 copies/mL in this
group.
3.5. Change in adherence score between T0 and T1
Among patients with T0 viraemia, the adherence score based on
the number of pills missed in the previous month improved from a
median of 1¢0 (IQR 1¢03¢0) at T0 to a median of 3¢0 (IQR 1¢03¢0) at
T1 (p<0¢0001). Among patients with T0 viral load 1000 copies/mL,
the median adherence score improved from 0¢0 (IQR 0¢01¢0) to 3¢0
(IQR 1¢03¢0) (p<0¢0001).
3.6. Resistance analysis
A total of 87 patients with sufﬁcient sample underwent resistance
testing, including 65/71 (91¢5%) with T0 viral load 1000 copies/mL
and 22/30 (73¢3%) with T0 viral load 200999 copies/mL. Prevalence
of RAMs according to the T0 viral load and ART regimen issummarised in Table 7. Prevalence of  1 NRTI, NNRTI or PI RAM was
53/87 (60¢9%), 59/87 (67¢8%) and 3/87 (3¢4%), respectively. Prevalence
of  1 RAM increased by T0 viral load stratum (Fig. 2A) and the GSS
decreased in parallel (Fig. 2B). No RAMs were detected in 15 patients
with viral load 200400 copies/mL. Among 12 patients with viral
load 400999 copies/mL, 4 (33¢3%) had  1 RAM, most commonly
M184V/I and K103N/S (Table 8). Patients with viral load
1000 copies/mL had more extensive resistance (median 2 RAMs;
[IQR 13], and more complex resistance patterns: 35/65 (53¢8% had
M184V/I and K103N/S, 20/65 (30¢8%) had  1 discriminatory RAM
(other than M184V/I), and 24/65 (36¢9%) had  1 TAM. CRF02_AG
was the most prevalent subtype (66/87, 75¢9%).
4. Discussion
In this prospective study of a mature HIV cohort accessing treat-
ment in a real-life setting in Ghana, POC viral load testing was techni-
cally feasible and effectively informed immediate adherence
counselling for patients with viraemia. After long-term, mainly
NNRTI-based ART in the absence of routine access to virological
Table 6
Univariable and multivariable logistic regression analysis of factors associated with lack of resuppression <1000 copies/mL at T1 among sub-
jects with T0 viral load 1000 copies/mL.
Variable Univariable analysis Multivariable analysisa
OR 95% CI p OR 95% CI p
Gender female vs male 1.19 0.403.50 0.75
Age per 5 years older 1.00 0.691.44 1.00
Enough food never vs at least some of the time 0.24 0.041.45 0.12
Alcoholb yes vs no 1.10 0.0912.8 0.94
Traditional or herbal remedies yes vs no 2.97 0.3327.1 0.33
Third agent PI/r vs NNRTI 0.12 0.011.11 0.06 0.34 0.034.24 0.40
NRTI backbone AZT/3TC vs TDF/3TC 1.88 0.675.30 0.23
Duration of ART per 1 year longer 1.04 0.901.20 0.60
Treatment interruptions 1 vs never 1.29 0.463.62 0.64
T1 VAS per 10% higher 0.67 0.470.98 0.036 0.54 0.290.99 0.047
Change in adherence score per unit increase 1.26 0.831.89 0.28
Time since HIV diagnosis per year longer 1.02 0.881.19 0.75
T0 CD4 count per 100 cells/mm3 higher 0.95 0.851.07 0.42
T0 viral load per 1 log10 copies/mL higher 1.14 0.622.06 0.68
T0 GSS scorec per 0¢5 higher 0.47 0.320.69 <0.001 0.43 0.270.69 <0.001
T0 NNRTI RAMs yes vs no 21.9 2.52190 0.005   
Abbreviations: ART=antiretroviral therapy; AZT=zidovudine; CI=conﬁdence interval; GSS=genotypic susceptibility score; NNRTI=non-nucleo-
side reverse transcriptase inhibitor; NRTI=nucleos(t)ide reverse transcriptase inhibitor; OR=odds ratio; PI/r=ritonavir-boosted protease
inhibitor; RAMs=resistance-associated mutations; 3TC=lamivudine; TDF=tenofovir disoproxil fumarate; VAS=visual analogue scale.
a Model 1 and Model 2 include the T0 viral load as a continuous and categorical variable respectively, and do not include the T0 GSS score;
Model 3 includes the T0 GSS and does not include the T0 viral load.
b Occasional or regular use.
c A GSS of 3 was arbitrarily assigned to patients with viral load <200 copies/mL and to 5 patients with viral load 200400 copies/mL that
did not yield a sequencing amplicon in 2 attempts (based on the absence of RAMs in other samples with viral load 200400 copies/mL).
Table 7
Prevalence of resistance-associated mutations (RAMs) according to the
T0 viral load and ART regimen.
ART regimen RAMs HIV-1 viral load (copies/mL)
200999 1000
NNRTI-based
Number tested 79 19 60
RAMs, n (%) None 14 (73.7) 7 (11.7)
NNRTI only 1 (5.3) 6 (10.0)
NRTI only 0 (0) 0 (0)
NRTI+NNRTI 0 (0) 47 (78.3)
NRTI+NNRTI+PI 0 (0) 1 (1.7)
No amplicon 4 (21.1) 0 (0)
PI-based
Number tested 13 8 5
RAMs, n (%) None 4 (50.0) 2 (40.0)
NNRTI only 0 (0) 0 (0)
NRTI only 1 (12.5) 1 (20.0)
NRTI+NNRTI 2 (25.0) 2 (40.0)
NRTI+NNRTI+PI 1 (12.5) 1 (20.0)
No amplicon 1 (12.5) 0 (0)
Abbreviation: ART=antiretroviral treatment; NNRTI=non-nucleoside
reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase
inhibitor; PI=protease inhibitor.
G. Villa et al. / EClinicalMedicine 18 (2020) 100231 7monitoring, nearly half of the patients had a detectable viral load, and
1 in 5 had a viral load 1000 copies/mL, the WHO-endorsed thresh-
old for deﬁning virological failure [3]. Eight weeks later, there was
high retention into follow-up. Although self-reported adherence lev-
els improved post-counselling, none of the patients with a viral load
1000 copies/mL achieved resuppression <40 copies/mL while con-
tinuing NNRTI-based ART, whereas a substantial proportion of those
with lower viral load levels did. We observed co-existence of high
viral loads and complex drug resistance patterns in the group with
viral load 1000 copies/mL, which suggests that delaying a switch to
second-line ART might be counterproductive in terms of risk of dis-
ease progression and potential transmission of drug-resistant strains.
Conversely, patients with viral load <1000 copies/mL had limited
drug resistance, increasing the likelihood of improved virological
control after adherence counselling. Of note, around a third ofpatients with viral load 1000 copies/mL showed a subsequent viral
load <1000 copies/mL while continuing NNRTI-based ART. There
remains uncertainty about the durability of partial virological
responses given the high risk of emerging drug resistance during
NNRTI-based therapy [32].
In pooled analyses of studies from sub-Saharan Africa, 65% and
62% of patients had a suppressed viral load (by intention to treat)
after 24 months of ﬁrst-line NNRTI-based ART and second-line PI/r-
based ART, respectively [19,20]. Rates of virological suppression differ
by region, and tend to be higher in randomised clinical trials than in
observational cohorts [20]. Long-term data are scarce. In this study,
after a median of 8¢9 years of predominantly NNRTI-based ART,
49¢2% had a detectable viral load and 21¢3% had 1000 copies/mL.
Similar alarming data were reported from Togo: after a median of
6 years of predominantly NNRTI-based ART, nearly 60% of patients
had viraemia, and 40% had a viral load 1000 copies/mL [21]. New
strategies are needed to improve management of HIV-positive
cohorts in West Africa, where care continues to be delivered largely
in the absence of virological monitoring.
In sub-Saharan Africa, POC assays were previously used effectively
for diagnosing HIV-positive infants, measuring CD4 cell counts, and
detecting tuberculosis [2224]. A trial from South Africa - a setting
with established virological monitoring capacity  recently reported
preliminary data showing that soon after ART initiation, POC viral
load testing by Xpert may promote higher retention in care and
greater virological suppression relative to standard laboratory testing
[25]. A previous multicentre study in rural Zimbabwe used Xpert for
on-site HIV-1 RNA testing of a selected population, but patients did
not wait for the results [26]. Adherence counselling was planned for
subjects with a viral load 1000 copies/mL; however, 13 weeks
after the initial viral load test, about half (53/96, 55%) of those with
viral load 1000 copies/mL were lost to follow-up. In our study, all
patients waited for their results, and all patients with any level of vir-
aemia received adherence counselling. Furthermore, perhaps anec-
dotally aided by the ﬁrst adherence counselling and knowledge that
results would be available on the same day, attendance at the follow-
up visit was 91¢5% among viraemic patients.
POC viral load testing was technically successful, and knowledge
of the result often unmasked problems with adherence that had not
Fig. 2. A) Prevalence of  1 resistance-associated mutation (RAM) by drug class and according to the T0 viral load; B) Box and whiskers of the genotypic susceptibility score (GSS)
according to the T0 viral load; for each viral load stratum, the box indicates the distribution of the score (median and IQR); the dotted line connects the median values of the score.
8 G. Villa et al. / EClinicalMedicine 18 (2020) 100231emerged at the ﬁrst interview a few hours earlier. However, imple-
mentation on a larger, routine scale requires a number of operational
solutions. Firstly, back-up batteries of sufﬁcient potency are required
to ensure continuous supply of electricity and avoid assay failure.
Second, the size of the Xpert unit dictates the number of tests that
can be run within a typical clinic day. Where larger or multiple units
are not available, strategies must be deﬁned to triage patients accord-
ing to their risk of viraemia. In our study, both a history of treatment
interruption and the VAS score were associated with the viral load.
Other studies from Mozambique [27], Nigeria, Uganda, Kenya and
Tanzania [28] similarly indicated that measured or self-reported
adherence independently predicted a viral load 1000 copies/mL.
Thus, simple measures of adherence could be applied to fast track
patients to POC vs. deferred viral load testing, a hypothesis that needs
investigating in controlled studies. Additional factors could be used to
develop a triaging score. For example, age, gender, food availability
and use of AZT/3TC versus TDF/3TC were predictors of viraemia in
this study.
A meta-analysis of 5 studies conducted between 2004 and 2013
explored rates of resuppression after adherence counselling in highand middle-low income countries, including Mali, Burkina Faso, Swa-
ziland, and South Africa [29]. A pooled estimate of 70% was derived
from a total population of 406 patients that differed in terms of treat-
ment history and deﬁnition of viraemia and resuppression. Resup-
pression rates following adherence counselling in patients with a
viral load 1000 copies/mL while receiving ﬁrst-line NNRTI-based
ART were reported from a trial in Uganda (resuppression rate 19/70,
27%) [4], a multicentre study from Burkina Faso, Cameroon, and Sene-
gal (81/584, 14%) [30], and a prospective study from rural Lesotho
(39/110, 35%) [31]. One important limitation of these studies was
that viral load testing was deferred and rates of loss to follow-up
ranged up to 33%. A study from Uganda also reported that adherence
levels (measured by electronic pill count) predicted the likelihood of
resuppression for patients with viral load 5001000 copies/mL, but
not for those with viral load 1000 copies/mL [5]. The available data
are in line with our ﬁndings. We found that the T0 viral load pre-
dicted the likelihood of resuppression <40 copies/mL independently
of self-reported adherence, whereas adherence levels (as well as
detection of RAMs) were independently predictive of resuppression
<1000 copies/mL among patients with viral load 1000 copies/mL.
Table 8
Types of resistance-associated mutations (RAMs) stratiﬁed by the T0 viral load.
Group T0 HIV-1 RNA (copies/mL)
200999 1000
n % n %
Total number testeda 22 100 65 100
NRTI RAMs Any 3 13¢6 50 76¢9
Discriminatory M184V/I 3 13¢6 48 73¢8
K65R   12 18¢5
K70E/G/N   7 10¢8
L74I/V 1 4¢5 5 7¢7
Y115F   3 4¢6
TAMs type 1 M41L 2 9¢1 12 18¢5
L210W 1 4¢5 6 9¢2
T215Y 2 9¢1 9 13¢8
TAMs type 2 D67N/G 1 4¢5 7 10¢8
K70R   8 12¢3
T215F   4 6¢2
K219Q/E/R 1 4¢5 14 21¢5
T215 revertants T215D/I/V   3 4¢6
Miscellaneous E44D 1 4¢5 2 3¢1
T69G   1 1¢5
NNRTI RAMs Any 4 18¢2 55 84¢6
A98G   10 15¢4
L100I   1 1¢5
K101E/H/P   9 13¢8
K103N/S 3 13¢6 43 66¢2
V108I 1 4¢5 10 15¢4
E138G/Q   5 7¢7
G190A/S   8 12¢3
Y181C   10 15¢4
Y188L   3 4¢6
H221Y   4 6¢2
P225H   16 24¢6
F227L   3 4¢6
M230L   5 7¢7
K238T 1 4¢5 6 9¢2
Y318F   1 1¢5
PI RAMsb Any 1 4¢5 2 3¢1
L33F   1 1¢5
M46I 1 4¢5 1 1¢5
L76V 1 4¢5  
V82A   1 1¢5
I84V 1 4¢5  
Abbreviations: IQR=interquartile range; NNRTI=non-nucleoside reverse tran-
scriptase inhibitor; NRTI=nucleos(t)itide reverse transcriptase inhibitor;
RAMs=resistance-associated mutations; PI=protease inhibitor; TAMs=thymi-
dine analogue mutations.
a HIV-1 subtypes comprised CRF02_AG (66/87, 75¢9%), CRF06_cpx (9/87,
10¢3%), A (5/87, 5¢7%), CRF09_cpx (4/87, 4¢6%), G (2/87, 2¢3%), and D (1/87, 1¢1%).
b The 3 subjects with PI RAMs had received lopinavir/ritonavir for a median of
0¢74 years (IQR 0¢081¢34).
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tinuum, a viral load 1000 copies/mL identiﬁed patients with exten-
sive drug resistance and reduced likelihood of resuppression while
continuing NNRTI-based ART.
In previous studies, prevalence of RAMs in NNRTI-treated patients
with viral load 1000 copies/mL was 89% (54/61) after a median of
3 years in Mozambique [27], 99% (440/446) after 4 years in Burkina
Faso, Senegal and Cameroon [30], 92% (77/84) after 5 years in Mali
[33], and 99% (163/164) after 6 years in Togo [21]. After a median of
8¢9 years of predominantly NNRTI-based ART in this study, 55/65
(85%) patients with viral load 1000 copies/mL had 1 RAM, usually
including multiple NRTI and NNRTI RAMs. We noted a relatively high
prevalence of tenofovir RAMs in this group, with 21/65 (32%) patients
showing K65R, K70E/G/N, L74I/V, or Y115F. As previously observed
by us [34] and others [30], the highly mutated virus strains did not
show evidence of impaired ﬁtness given the high viral loads and low
CD4 cell counts. Tenofovir remains a key component of ﬁrst- and sec-
ond-line ART in sub-Saharan Africa, including forthcoming regimens
with dolutegravir. It will be important to monitor the impact oftenofovir RAMs in treated populations and assess the risk of trans-
mission and impact on the efﬁcacy of pre-exposure prophylaxis.
There are limitations to this study. For most patients, there had
been no previous viral load measurement to guide treatment deci-
sions, and the ﬁndings may not directly apply to different epidemio-
logical contexts where virological monitoring is already established.
As the cohort had no routine access to viral load testing, no rando-
mised comparison with standard of care was possible. Given the pilot
nature of the study and the need to obtain initial data on rates of vir-
aemia and associated risk factors, no attempt was made at exploring
same-day versus deferred POC viral load testing; controlled studies
are planned to determine the optimal strategy for triaging patients.
Whilst it may be argued that longer follow-up or a different modality
of adherence counselling might have improved responses in the
group with viral load 1000 copies/mL, the high prevalence of NRTI
and NNRTI RAMs makes such outcomes unlikely. Direct measures
such as pill-counts could have enhanced the evaluation of adherence,
although there is evidence that self-reported measures may perform
better than pill-counts in these settings [35]. Detection of RAMs by
population sequencing might have failed to detect low-frequency
variants. However, we previously documented that in a population
long established on NNRTI-based ART deep sequencing affords a
rather modest increase in yield [34].
In conclusion, the current WHO-endorsed two-stage algorithm,
whereby a switch to a second-line regimen is recommended only if a
viral load measurement 1000 copies/mL is conﬁrmed 36 months
after adherence counselling, may be regarded as most effective in set-
tings with a low prevalence of NNRTI resistance. In settings with high
population-level estimates of NNRTI resistance, and especially when
testing patients who have received long-term NNRTI-based ART with-
out virological monitoring, a viral load measurement1000 copies/mL
is typically accompanied by high rates of NRTI and NNRTI drug resis-
tance and can be used to trigger a switch to second-line ART without
waiting for the conﬁrmatory measurement.5. Contributors
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